Promaxo Incorporates Subsidiary Focused on Portable Head and Brain MRI

In partnership with renowned imaging research center, Neuro42 to commercialize technology that helps physicians triage patients with neurological diseases and injuries sooner

OAKLAND, Calif.–(BUSINESS WIRE)–Promaxo, Inc. (Promaxo), a medical imaging, robotics and AI technology company, announced today the incorporation of a subsidiary that expands on its foothold in technologically advanced magnetic resonance imaging. Neuro42, Inc. is focused on the development and commercialization of portable head and brain MRI for diagnosis and interventions of neurological conditions.

Neuro42 has an exclusive worldwide license of the low-field MR imaging technology developed at Dr. Lawrence Wald’s lab at the Athinoula A. Martinos Center for Biomedical Imaging, a world-renowned magnetic resonance research center that touts an affiliation with Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University.

“With this partnership with Martinos Center, we believe that Neuro42 can revolutionize the way physicians identify and treat neurological diseases and injuries,” said Dr. Amit Vohra, Co-Founder and CEO of Promaxo. “As a company, Promaxo has vowed to commercialize technologies that provide a substantial impact for people in medical need, and Neuro42 reaffirms that pledge.”

Neuro42 was formed to exclusively focus on brain imaging for the purpose of triaging, screening, diagnosing and intervening in the treatment of various brain conditions that range from traumatic brain injury to epilepsy and brain tumors.

“We all recognize the prevalence of neurological diseases in today’s society, and the need for technology that aids in combating these conditions has never been more clear,” Dr. Wald said. “By partnering with a company like Promaxo that understands and appreciates both technology and patient-centered care, we believe Neuro42 is primed to make a significant global impact on how head and brain MRIs are performed.”

One of the most significant advantages of the technology Neuro42 is bringing to market is that the novel magnetic resonance scanner allows for earlier triaging of patients, creating a point of care shift for patients with brain injuries and those who have experienced a stroke.

Additionally, the low-field MRI will facilitate the use of direct robotic interventions outside of the traditional magnetic resonance surgical suite.

For more information on Neuro42 and Promaxo, visit neuro42.ai and promaxo.com.

About Promaxo, Inc.

Promaxo is a medical technology company developing a minimally invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 60 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient screening and interventions. The company has formed numerous long-term and strategic partnerships with investor groups as it prepares to enter the U.S. market.

To learn more about the technology behind the MRI system and its scope, visit: promaxo.com.

LinkedIn: Promaxo
Twitter: @Promaxo
Facebook: Promaxo

About Neuro42, Inc.

Neuro42, Inc. is a medical technology company focused on imaging and image guided interventions of the brain. To learn more about Neuro42, visit neuro42.ai.

Contacts

Jive PR + Digital

Lindsey Hill

lindseyhill@jiveprdigital.com
951.566.6413

www.jiveprdigital.com